Budesonide

• Studio clinico pilota: utilizzo di una nuova formulazione di Budesonide Viscosa in bambini con Esofagite Eosinofila - BUDEOE Not authorised
  2024-512395-36-00 Phase II 1 country University Hospital Consorziale Policlinico; University Of Bari Aldo Moro
• Evaluation of the efficacy and safety of prolonged-release budesonide in children with primary IgA nephropathy. Pending
  2024-518759-45-00 Phase III 1 country Medical University Of Warsaw
• A clinical trial to evaluate the efficacy and safety of a mixture of allergenic extracts of D. pteronyssinus and D. farinae, in patients suf… Pending
  2025-521230-29-00 Phase III 1 country LETI Pharma S.L.U.
• Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT Pending
  2025-522694-11-00 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of a rectal treatment with budesoni… Recruiting
  2024-519359-27-00 Phase II 2 countries Dr. Falk Pharma GmbH
• C0251006 - A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN … Recruiting
  2022-502739-20-00 Phase III 10 countries Pfizer Inc.
• A prospective, randomized, double-blind, placebo-controlled, multicentre, dose-finding clinical trial with polymerised mannan-conjugated all… Recruiting
  2025-524580-21-00 Phase II/III 1 country Inmunotek S.L.
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin i… Recruiting
  2024-518365-10-00 Phase III 12 countries F. Hoffmann-La Roche AG
• An open-label extension study with dazukibart for participants with idiopathic inflammatory myopathies (including DM or PM) who have complet… Recruiting
  2024-514648-10-00 Phase III 6 countries Pfizer Inc.
• Molecular signatures associated with response to ICS treatment in patients with COPD stratified by eosinophil levels Recruiting
  2023-505245-13-00 Phase IV 3 countries Fundacio De Recerca Clinic Barcelona-Institut D’investigacions Biomediques Augus…
• A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting
  2023-509096-16-00 Phase IV 8 countries Alimentiv Inc.
• Budesonide as a treatment for inflammation in stomach complaints. Recruiting
  2024-517035-43-00 Phase IV 1 country UZ Leuven
• A study to evaluate the efficacy and safety of QMF149 (indacaterol acetate/mometasone furoate) versus Budesonide in children from 6 to less … Recruiting
  2022-501899-26-00 Phase III 9 countries Novartis Pharma AG
• A study to look at how safe divarasib is when given on its own or in combination with other anti-cancer therapies, and how well these medici… Recruiting
  2023-507171-22-00 Phase I/II 6 countries F. Hoffmann-La Roche AG
• A study of Vedulizumab in Children and Teenagers with Moderate to Severe Crohn's Disease (CD) Recruiting
  2023-509045-13-00 Phase III 6 countries Takeda Development Center Americas Inc.
• Clinical study to demonstrate the same clinical efficacy and tolerability of budesonide orodispersible tablets (taken twice a day compared t… Recruiting
  2024-515229-26-00 Phase III 4 countries Dr. Falk Pharma GmbH
• Efficacy and safety of subcutaneous dupilumab in participants with asthma/asthmatic wheeze aged 2 to <6 years Ended
  2023-504331-41-00 Phase III 9 countries Sanofi-Aventis Research & Development
• A prospective, randomized, double-blind placebo-controlled multicentre trial with mannan-conjugated birch pollen allergoids administered sub… Ended
  2024-515717-17-00 Phase III 1 country Inmunotek S.L.
• Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and… Ended
  2024-519269-23-00 Phase III 1 country Medical University Of Warsaw
• Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler in Patients with Inadequately Controlled Asthma Ended
  2024-513568-24-00 Phase III 3 countries AstraZeneca AB
• Double-blinded (treatment group unknown to physician and patient), randomised (treatment group allocated by chance) phase II trial on the ef… Ended
  2023-507897-42-00 Phase II 7 countries Dr. Falk Pharma GmbH
• Efficacy and safety of the intratracheal administration of budesonide with surfactant in very preterm infants to prevent bronchopulmonary dy… Ended
  2024-519980-16-00 Phase III 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…

Showing 1–22 of 22 trials